RxDoctor Payments Data

Linda Habeeb, MD

Internal Medicine · Sandwich, MANPI 1619927035

Payments from drug & device makers

$456in general payments, 2019–2025

Across 17 payments — averaging $26.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$203
  • Novo Nordisk$110
  • Abbott$87
  • Dexcom, Inc.$25
  • Astellas Pharma US Inc$20
  • Pfizer$11

What the payments were for

  • Food & beverage$456100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie4$203
Novo Nordisk6$110
Abbott4$87
Dexcom, Inc.1$25
Astellas Pharma US Inc1$20
Pfizer1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$456 in reported general payments places this provider in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$265,232
Medicare patients
538
Services billed
2,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$65,696
Breo ElliptaFluticasone/Vilanterol47$22,152
XareltoRivaroxaban16$17,094
OzempicSemaglutide17$14,806
Rosuvastatin Calcium353$11,661
JardianceEmpagliflozin14$10,657
Atorvastatin Calcium436$5,377
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$5,235
Potassium Chloride54$4,646
Wixela InhubFluticasone Propion/Salmeterol46$4,641
Levothyroxine Sodium395$4,285
Omeprazole297$4,143
Ezetimibe63$3,938
Amlodipine Besylate450$3,224
Metoprolol Succinate140$2,853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$65,69671 claims
Novo NordiskOzempic$110$14,80617 claims
AbbVieSynthroid$203$2,83061 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Sandwich

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →